Chlormadinone Acetate

Summary

Chlormadinone Acetate (CHEMBL110691) is an approved small molecule (ATC G03DB06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03DB06
• Clinical trials: 2
• Chemistry: 404.9 Da · C23H29ClO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL110691
Name	Chlormadinone Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9324
ATC	G03DB06
Molecular formula	C23H29ClO4
Molecular weight	404.9
InChIKey	QMBJSIBWORFWQT-DFXBJWIESA-N

SMILES: CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C

IUPAC name: [(8R,9S,10R,13S,14S,17R)-17-acetyl-6-chloro-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate

Also known as: Chlormadinone, Chlormadinone acetate, Clormadinona, Lutoral, Normenon, NSC-92338, RS-1280, SID29215009, SID855775, SID56422443, Chlormadinone Acetate, CHLORMADINONE ACETATE

Patent coverage: 4,348 distinct patent families (9,747 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Survival motor neuron protein, Fructose-bisphosphate aldolase, Ferritin light chain, Androgen receptor, Thyroid hormone receptor beta, Glucocorticoid receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 24 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204424
AR	8.13	AC50	7.4	nM	CHEMBL_ACT_25203491
THRB	8.1	Potency	7.9	nM	CHEMBL_ACT_4019929
NR3C1	7.76	Ki	17.2	nM	CHEMBL_ACT_7694748
P15207	7.68	Ki	20.9	nM	CHEMBL_ACT_7696930
P15207	7.5	IC50	31.3	nM	CHEMBL_ACT_7696929
NR3C1	7.42	IC50	37.7	nM	CHEMBL_ACT_7694747
HIF1A	7	Potency	100	nM	CHEMBL_ACT_4131591
HIF1A	7	Potency	100	nM	CHEMBL_ACT_4519114
CYP2C19	5.52	IC50	3000	nM	CHEMBL_ACT_7694715
MAPK1	5.3	Potency	5012	nM	CHEMBL_ACT_4721445
NPSR1	5.3	Potency	5012	nM	CHEMBL_ACT_4900793
P02791	5.15	Potency	7080	nM	CHEMBL_ACT_4461772
CHRM1	5.01	AC50	9850	nM	CHEMBL_ACT_25210326
SMN1	5	Potency	10000	nM	CHEMBL_ACT_3864470

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01123538	PHASE4	UNKNOWN	Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile
NCT01608698	PHASE4	UNKNOWN	Comparison of Body Weight Change During Contraception With Belara and Yasmin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).